Send a Tweet
Most Popular Choices
Poll Analyses
Share on Facebook 2 Share on Twitter Printer Friendly Page More Sharing
General News    H4'ed 11/27/15

Martin Shkreli walks back on pledge to lower price of HIV drug Daraprim

Follow Me on Twitter     Message Sheila Samples
Become a Fan
  (49 fans)
Price Gouging Drug CEO Martin Shkreli
Price Gouging Drug CEO Martin Shkreli
(Image by The Young Turks, Channel: TheYoungTurks)
  Details   DMCA

Controversial pharmaceutical boss Martin Shkreli has has decided he’s not going to lower the price of his HIV medication after all. Shkreli’s company Turing Pharmaceuticals announced on Wednesday that it would provide volume discounts of its drug Daraprim to hospitals, but it appears that the company’s $750-a-pill price tag still stands. Turing and Shkreli attracted a firestorm of criticism in September after it was revealed the company had raised the price of Daraprim, a 62-year-old treatment for parasitic infections, to $750 a pill from $13.50 after acquiring it. The medicine once sold for $1 a pill.
Read the rest of the story HERE:

At www.theguardian.com

 

Must Read 1   Valuable 1  
Rate It | View Ratings

Sheila Samples Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Sheila Samples is an Oklahoma writer and a former civilian US Army Public Information Officer. She is a Managing Editor for OpEd News, and a regular contributor for a variety of Internet sites.

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Follow Me on Twitter     Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

To View Comments or Join the Conversation: